Immuntherapie urologischer Tumoren
- 18 September 2017
- journal article
- fortbildung
- Published by Springer Nature in Info Onkologie
- Vol. 20 (S1) , 28-35
Abstract
No abstract availableKeywords
This publication has 46 references indexed in Scilit:
- Coinhibitory Pathways in Immunotherapy for CancerAnnual Review of Immunology, 2016
- Targeting PD-1/PD-L1 in the treatment of metastatic renal cell carcinomaTherapeutic Advances in Urology, 2015
- Survival Outcome and Treatment Response of Patients with Late Relapse from Renal Cell Carcinoma in the Era of Targeted TherapyEuropean Urology, 2014
- Current and future systemic treatments for renal cell carcinomaSeminars in Cancer Biology, 2013
- Sipuleucel-T Immunotherapy for Castration-Resistant Prostate CancerNew England Journal of Medicine, 2010
- Ipilimumab (Anti-CTLA4 Antibody) Causes Regression of Metastatic Renal Cell Cancer Associated With Enteritis and HypophysitisJournal of Immunotherapy, 2007
- Intravesical bacille calmette-guérin versus mitomycin c in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progressionUrology, 2004
- B7-CD28 interaction is a late acting co-stimulatory signal for human T cell responsesInternational Immunology, 1997
- Interferon in renal cell carcinoma. The UCLA experienceCancer, 1987
- Intracavitary Bacillus Calmette-guerin in the Treatment of Superficial Bladder TumorsJournal of Urology, 1976